Linezolid: Difference between revisions

Latest revision as of 06:01, 12 September 2024

Citable Version ^[?]

This editable Main Article is under development and subject to a disclaimer.

[edit intro]

Linezolid is the first commercially available antibiotic of the oxazolidinone class, approved for complex vancomycin-resistant Enterococcus faecium infections, methicillin-resistant Staphylococcus aureus, and complex Streptococcus pyogenes and S. agalactiae infections. It is approved for complex skin and soft tissue infections, and for pneumonias.

It has little activity against Gram-negative organisms. The drug can be given intravenously or orally.

Revision as of 12:56, 26 November 2010 (view source) imported>Howard C. Berkowitz No edit summary ← Older edit		Latest revision as of 06:01, 12 September 2024 (view source) Suggestion Bot (talk \| contribs) mNo edit summary
Line 2:		Line 2:
	'''Linezolid''' is the first commercially available [[antibiotic]] of the [[oxazolidinone]] class, approved for complex vancomycin-resistant ''[[Enterococcus faecium]]'' infections, methicillin-resistant ''[[Staphylococcus aureus]]'', and complex ''[[Streptococcus pyogenes]]'' and ''S. agalactiae'' infections. It is approved for complex skin and soft tissue infections, and for [[pneumonia]]s.		'''Linezolid''' is the first commercially available [[antibiotic]] of the [[oxazolidinone]] class, approved for complex vancomycin-resistant ''[[Enterococcus faecium]]'' infections, methicillin-resistant ''[[Staphylococcus aureus]]'', and complex ''[[Streptococcus pyogenes]]'' and ''S. agalactiae'' infections. It is approved for complex skin and soft tissue infections, and for [[pneumonia]]s.

	It has little activity against [[Gram stain\|Gram-negative]] organisms. The drug can be given intravenously or orally.		It has little activity against [[Gram stain\|Gram-negative]] organisms. The drug can be given intravenously or orally.[[Category:Suggestion Bot Tag]]